by Lisa Jarvis, Bloomberg Opinion Credit: Unsplash/CC0 Public DomainThe biggest quandary in the obesity drug market is that nobody knows just how big it will be. Everyone agrees it’ll be huge—currently, Eli Lilly & Co. is worth more than Tesla Inc., and Novo Nordisk A/S is at times the most valuable company in Europe. But...
